Randomized Trialhigh evidence
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England)·September 12, 2026·PMID 42721980
Why it mattersTransfusion-dependent thalassaemia currently lacks oral disease-modifying therapies, leaving patients reliant on chronic transfusions and chelation. Mitapivat offers a novel mechanism—pyruvate kinase activation—that may reduce transfusion burden and improve quality of life.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled